Drosophila, despite being a useful genetic model of development, have very little DNA methylation on C. What they do have is methylation on A (technically, N6-methyladenine), although little was known about what this modification did for Read more
Jeffrey Koplan, MD, MPH, director of the Emory Global Health Institute and vice president for Global Health at Emory University, is leading the second phase of the Tobacco Free Cities project in China, funded by the Bill and Melinda Gates Foundation. The project, which launched in 10 Chinese cities this week, is a partnership with the ThinkTank Research Center for Health Development in Beijing.
Vice mayors of each of the 10 cities signed an official pledge to strive to create tobacco-free cities for residents. China has more than 300 million smokers, the most of any country, and more than 500 million people in China are exposed to secondhand smoke.
â€œThe two-year project aims to enhance the overall capacity in smoking-tobacco control of the cities and help ease the burden caused by tobacco to public health, the environment and the economy,â€ Koplan says in an article in China Daily.
The project launch was covered by other major Chinese news outlets, including Xinhua News Agency.
The first phase of the Tobacco Free Cities project launched in June 2009 in seven Chinese cities. The project is part of the Emory Global Health Institute-China Tobacco Partnership. In January 2009 Emory University received a $14 million, five-year grant from the Gates Foundation to establish the partnership.
â€œOther states wish they had what Georgia has: Research universities that work together, and a unified commitment from industry, government and academia to grow a technology-based economy,” states Michael Cassidy, president and CEO of the Georgia Research Alliance (GRA) in the GRAâ€™s recent annual report.”
As one of six GRA universities, Emory has benefited from this unique partnership in numerous ways: through its 11 Eminent Scholars, multidisciplinary university and industry collaborations, and support for research in vaccines, nanomedicine, transplantation, neurosciences, pediatrics, biomedical engineering, clinical research, and drug discovery.
Emory is featured throughout the report, including
The Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory and its four eminent scholars, Xiaoping Hu, PhD, Eberhard Voit, PhD, Barbara Boyan, PhD and Don Giddens, PhD.
Emory transplant medicine expert and GRA Eminent Scholar Allan Kirk, MD, PhD, who collaborates with Andrew Mellor, PhD at the Medical College of Georgia on research to find enzymes that could keep the body from rejecting newly transplanted organs.
The Emory-University of Georgia Influenza Center of Excellence and its leading collaborators, GRA Eminent Scholar and Emory Vaccine Center Director Rafi Ahmed, PhD, and Emory microbiologist Richard Compans, PhD, along with UGA GRA Eminent Scholar Ralph Tripp.
Former National Institutes of Health director Elias Zerhouni created a vivid label for a persistent problem. He noted there was a widening gap between basic and clinical research. The “valley of death” describes the gap between basic research, where the majority of NIH funding is directed and many insights into fundamental biology are gained, and patients who need these discoveries translated to the bedside and into the community in order to benefit human health. Thus, a chasm has opened up between biomedical researchers and the patients who would benefit from their discoveries.
Translational research seeks to move ideas from the laboratory into clinical practice
Translational research seeks to move ideas from the laboratory into clinical practice in order to improve human health.
A new certificate program in translational research is designed to empower PhD graduate students to bridge that gap. Participants (PhD graduate students) from Emory, Georgia Tech and Morehouse School of Medicine can take courses in epidemiology, biostatistics, bioethics, designing clinical trials and grant writing, and will have rotations with clinicians and clinical interaction network sites where clinical research studies are carried out to get a better sense of the impact and potential benefit of the research they are conducting.
The initiative, launched March 2 by the Northrop Grumman Corporation, aims to unite higher education and the private sector to accelerate the application of thought leadership to global public health informatics, policy development, strategic planning, programmatic implementation and evaluation.
The grant will allow Childrenâ€™s and Emory to expand their research partnership, attract top scientists, and advance research discoveries that will improve the health of children.
Some of the pediatric research conducted in a new building to be built on the Emory campus will focus on cardiology, cancer, vaccines, and new drug discovery. The grant has implications for the city of Atlanta as a growing research community, building on collaborations among Childrenâ€™s Healthcare, Emory, Georgia Institute of Technology, Morehouse School of Medicine, and others.
Fred Sanfilippo, MD, PhD, executive vice president for health affairs at Emory, and Donna W. Hyland, president and CEO of Children’s Healthcare of Atlanta, explained that the new grant, which is the largest single gift ever to Children’s, will have an enormous impact on the two institutions, building on the strong partnership between Emory and Children’s and leading them to become a major pediatric research hub in the Southeast and the nation. Most importantly, it will help in finding cures for some of the most common and devastating childhood diseases.
Knechtle is chief of the Emory School of Medicine transplant division and professor of surgery, and surgical director of Childrenâ€™s Liver Transplant Program. Childrenâ€™s Liver Transplant program was founded in 1990 and has completed more than 300 liver transplants.
The liver transplant team is made up of many individuals who contribute to its success – liver transplant surgeons, transplant hepatologists (doctors with expertise in the treatment of the liver), and a team of gastroenterologists, anesthesiologists, pathologists, radiologists, mental health specialists, chaplains, nurses, social workers and pharmacists.
For more than 20 years, Emory and Childrenâ€™s physicians have been at the forefront of pediatric transplant care, achieving several groundbreaking accomplishments, including:
Transplanted the worldâ€™s youngest (10 days old) and three smallest (2 to 4 pounds) liver transplant recipients
One of the first pediatric hospitals in the United States to perform three heart transplants in 24 hours
At the forefront of its field with ABO-incompatible liver and heart transplants
Performed more than 450 pediatric kidney transplants.
Children’s kidney transplant recipient Quinn Roberts, age 8, with her donor Cheryl Thomas
Over the past twenty years, the research partnership between Emory University and the Georgia Institute of Technology has developed into one of the leading bioengineering and biomedical research and educational programs in the nation. In recent years this partnership has resulted in the development of several pieces of diagnostic and medical-assistant technology, with medical experts on the Emory side working with engineers on the Georgia Tech side.
An example of this collaboration is the El-E robot, designed to perform simple tasks such as opening drawers and retrieving objects. Clinicians at Emoryâ€™s School of Medicine and engineers at Georgia Tech created the 5Â½-foot-tall machine, which glides across the floor on wheels and takes direction from a laser pointer that users can control in a variety of ways, depending on their preferences and capabilities. El-E is no mere toy, however: The machine could help patients with significant motor impairments, such as sufferers of ALS, maintain their independence and help relieve physical and financial burdens faced by caregivers.
Another result of the Emory-Georgia Tech collaboration is DETECT, a portable device capable of detecting the earliest stage of Alzheimer’s disease, mild cognitive impairment, in any environment. DETECT has a helmet device that includes an LCD display in a visor, along with a computer and noise-reduction headphones. DETECT gives the patient a battery of words and pictures to assess cognitive abilitiesâ€”reaction time and memory capabilities. The low-cost test takes approximately 10 minutes. The device was co-developed by emergency medicine physician David Wright, and Michelle LaPlaca, a scientist in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory.